CD7

Chr 17

CD7 molecule

Also known as: GP40, LEU-9, TP41, Tp40

This gene encodes a transmembrane protein which is a member of the immunoglobulin superfamily. This protein is found on thymocytes and mature T cells. It plays an essential role in T-cell interactions and also in T-cell/B-cell interaction during early lymphoid development. [provided by RefSeq, Jul 2008]

11
Active trials
83
ClinVar variants
22
Pathogenic / LP
0.5
Missense Z
1.07
LOEUF
12
Pubs (2 yr)
Clinical SummaryCD7
Population Constraint (gnomAD)
Low constraint (pLI 0.05) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
22 Pathogenic / Likely Pathogenic· 50 VUS of 83 total submissions
💊
Clinical Trials
11 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — CD7
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
Some data sources returned errors (1)

ensembl: TimeoutError: The operation was aborted due to timeout

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.07LOEUF
pLI 0.051
Z-score 1.45
OE 0.42 (0.191.07)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.54Z-score
OE missense 0.88 (0.761.01)
133 obs / 151.7 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.42 (0.191.07)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.88 (0.761.01)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.99
01.21.6
LoF obs/exp: 3 / 7.2Missense obs/exp: 133 / 151.7Syn Z: 0.08

ClinVar Variant Classifications

83 submitted variants in ClinVar

Classification Summary

Pathogenic19
Likely Pathogenic3
VUS50
Likely Benign11
19
Pathogenic
3
Likely Pathogenic
50
VUS
11
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
19
0
19
Likely Pathogenic
0
0
3
0
3
VUS
0
41
9
0
50
Likely Benign
0
9
1
1
11
Benign
0
0
0
0
0
Total05032183

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CD7 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

T-CELL ANTIGEN CD7; CD7
MIM #186820 · *
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Top 10 resultsSearch PubMed ↗
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
PubTator3
CD7 CAR: sword and shield
Velasquez MP et al.·Blood
2022
CD7 CAR-T T 1
Huang HJ et al.·Zhonghua Xue Ye Xue Za Zhi
2023
Top 10 full-text resultsSearch PubTator3 ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

T-cell Acute Lymphoblastic LymphomaT-non-Hodgkin LymphomaT-cell Acute Lymphoblastic Leukemia

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

RECRUITING
NCT03690011Phase PHASE1Baylor College of MedicineStarted 2021-08-02
CD7.CAR/28zeta CAR T cells
T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

RECRUITING
NCT06934382Phase PHASE1Stephan Grupp MD PhDStarted 2025-04-29
Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Lung Cancer

Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy

RECRUITING
NCT03578185Se-Hoon LeeStarted 2018-04-11
AutophagyGalectinsHIV Infections

Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

RECRUITING
NCT04160455Centre Hospitalier Régional d'OrléansStarted 2019-11-07
expression of a panel
Mycosis Fungoides/Sezary SyndromeCutaneous T Cell Lymphoma

Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study

NOT YET RECRUITING
NCT06651203Assistance Publique - Hôpitaux de ParisStarted 2024-11-01
Follow-up
T-Cell Acute Lymphocytic Leukemia

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

ACTIVE NOT RECRUITING
NCT05909527Phase PHASE1, PHASE2Guangzhou Bio-gene Technology Co., LtdStarted 2023-05-01
CD7 CAR-T
Inflammatory Bowel DiseasesCrohn Disease

Predicting IBD Treatment Outcomes With Gut Microbiome Analysis

RECRUITING
NCT06453720University of British ColumbiaStarted 2024-08-01
Colonoscopy
CD7-Positive Hematological Malignancies

Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies

NOT YET RECRUITING
NCT07345780Phase NADonghua ZhangStarted 2026-12-31
CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL

RECRUITING
NCT06064903Phase PHASE1, PHASE2Bambino Gesù Hospital and Research InstituteStarted 2024-04-21
CD7-CART01
T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaAcute Myeloid Leukemia

Universal 4SCAR7U Targeting CD7-positive Malignancies

RECRUITING
NCT05995028Phase PHASE1Shenzhen Geno-Immune Medical InstituteStarted 2023-10-31
Universal CD7-specific CAR gene-engineered T cells
Prolymphocytic LeukemiaT-cell Leukemia

Observatory of Prolymphocytic Leukemia T

RECRUITING
NCT04411043French Innovative Leukemia OrganisationStarted 2020-07-01
Molecular caracterization